ORGO
Organogenesis Holdings Inc.
$2.40
-0.06 (-2.44%)
At close · Jul 10
Market Cap
$308.82M
Shares
128,674,548
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.40
Open$2.47
Day$2.36–2.47
52W$2.04–7.08
Avg vol 30d775K
Short int13.8M · 10.7% float · 16.3d
Short vol43%
Last earningsMay 7, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 7
Up next
Next earnings call
Aug 6, 2026
Est · unconfirmed
· in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−33%
below
Price vs 50-day avg
−3%
below
RSI (14)
47
neutral
MACD trend
Positive
52-week position
7%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−3%
trailing
6-month return
−40%
trailing
YTD return
−54%
this year
Relative strength
−49%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $4 — 200d above 50d
Institutional flow
Distributing
4 of 120 funds reported for Jun 30 · net -1.6K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
10.73% of float · ▲ +12.4% MoM · 16.3 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
120 holders — mid 3-yr range
Squeeze score
76
high risk · 0–100
Fundamentals
Revenue growth
+17%
Y/Y
Gross margin
65%
contracting
EPS growth
+1600%
Y/Y
Free cash flow
$-24.5M
Balance sheet
$27.1M
net cash
Quant / Vol
risk profile
Volatility
76%
annualized · 1-yr
Max drawdown
−66%
past year
ATR
5.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−33%
Bearish
Price vs 50-day avg
−3%
Neutral
RSI (14)
47
Neutral
MACD trend
Positive
Bullish
52-week position
7%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $4 — 200d above 50d
Institutional flow
Distributing
4 of 120 funds reported for Jun 30 · net -1.6K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
10.73% of float · ▲ +12.4% MoM · 16.3 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
120 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $2
Now $2 · 7%
52-wk high $7
vs 200-day avg -33%
vs 50-day avg -3%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA loss non-GAAP | $48.2M | the first quarter of 2026 | — |
| Adjusted net loss non-GAAP | $43.7M | the first quarter of 2026 | — |
| Adjusted EBITDA non-GAAP | $84.2M | the fourth quarter of 2025 | — |
| Adjusted net income non-GAAP | $52.9M | the fourth quarter of 2025 | — |
| Non-GAAP operating income non-GAAP | $75.9M | the fourth quarter of 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ORGO
this stock
Organogenesis Holdings Inc.
|
$308.82M | -53.7% | +17.0% | — | 10.7% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$52.88B | +6.2% | — | — | 0.2% |
|
GALDY
Galderma Group AG/ADR
|
$50.15B | +3.2% | — | — | 0.0% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$45.13B | — | — | — | 0.0% |
|
HLN
Haleon plc
|
$42.98B | -3.5% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ORGO | +1.7% | -2.8% | -39.6% | -1.2% | -53.7% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | +0.3% | -6.9% | -48.6% | -2.3% | -64.4% |